An in-depth analysis of ER+ breast cancer, focusing on its prevalence, molecular biology, current treatments, and emerging ...

Of course, science around estrogen and menopause—a noteworthy time of estrogen loss—is largely lacking: Research suggests ...

Since 1999, the American opioid epidemic has killed more than half a million people, and the staggering majority have been ...

A study finds that male rats in chronic pain escalate fentanyl use, while females maintain stable doses due to estrogen’s ...

Check hormone-balancing breakfast options loaded with nutrient-rich foods like flaxseeds, avocados, and chia seeds to support ...

PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...

Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...